CAPR · As filed with the SEC
Capricor Therapeutics cash flow statement, by fiscal year
The statement as Capricor Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Net loss | — | — | — | — | — | (13,657,028) | (7,641,817) | (15,191,095) |
| Net loss | (105,043,946) | (40,467,186) | (22,287,542) | (29,019,532) | (20,022,520) | — | — | — |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Loss on disposal of fixed assets | 157,519 | 112,805 | 6,041 | 34,266 | 7,905 | 0 | 2,720 | — |
| Depreciation and amortization | 1,889,041 | 1,425,214 | 1,068,882 | 533,131 | 245,697 | 143,890 | 171,956 | 157,652 |
| Stock-based compensation | — | 9,765,164 | 7,392,396 | 4,458,578 | 2,965,692 | 1,952,679 | 700,984 | 1,725,590 |
| Forgiveness of loan payable | — | — | — | — | — | — | — | 0 |
| Forgiveness of debt | — | — | — | 0 | (318,160) | — | — | — |
| Stock-based compensation | 16,967,799 | — | — | — | — | — | — | — |
| Restricted stock awards granted | 257,461 | — | — | — | — | — | — | — |
| Changes in lease liabilities | 715,459 | (47,261) | (24,282) | 161,740 | 129,726 | — | — | — |
| Non-cash interest expense on CIRM liability | 3,045,725 | — | — | — | — | — | — | — |
| Changes in operating assets and liabilities: | ||||||||
| Receivables | 10,309,322 | 3,504 | (9,824,413) | (155,830) | (391,750) | 87,968 | 116,900 | 139,707 |
| Prepaid expenses and other current assets | — | — | — | — | (148,728) | (439,827) | 152,802 | (223,020) |
| Prepaid expenses and other assets | (4,093,633) | (458,653) | (75,884) | 240,045 | — | — | — | — |
| Other assets | — | — | 0 | 7,550 | (187,021) | 30,907 | 32,180 | (55,819) |
| Accounts payable and accrued expenses | 5,983,992 | 1,941,136 | 1,388,078 | 1,718,312 | 400,750 | 1,826,601 | (273,175) | (347,398) |
| Accounts payable and accrued expenses, related party | — | — | — | — | — | — | (84,051) | (68,058) |
| Accrued interest | — | — | — | — | — | — | — | 0 |
| CIRM liability | — | — | — | — | — | — | — | 0 |
| Deferred revenue | — | — | — | — | — | — | — | 0 |
| Accounts payable and accrued expenses, related party | — | — | — | — | 590,416 | — | — | — |
| Operating lease liabilities | — | — | — | — | (81,331) | — | — | — |
| Accounts payable and accrued expenses, related party | — | — | (61,755) | (510,154) | — | — | — | — |
| Deferred revenue | 0 | (12,270,465) | (3,178,066) | 27,448,531 | — | — | — | — |
| Net cash used in operating activities | (69,811,261) | (39,995,742) | (25,596,545) | 4,916,637 | (16,809,324) | (10,054,810) | (6,821,501) | (13,862,441) |
| Cash flows from investing activities: | ||||||||
| Purchase of marketable securities | (151,392,398) | (208,441,162) | (97,441,506) | (114,218,737) | 0 | (6,130,193) | (6,002,050) | (18,011,577) |
| Proceeds from sales and maturities of marketable securities | 260,595,875 | 93,796,269 | 104,597,249 | 82,505,961 | 0 | 12,117,000 | 3,000,000 | 23,000,000 |
| Purchases of property and equipment | (2,904,461) | (1,166,871) | (1,311,660) | (2,000,243) | (1,196,286) | (547,601) | 0 | (316,486) |
| Payments for leasehold improvements | (383,539) | (372,104) | (735,873) | (1,359,488) | — | — | — | — |
| Payments for construction in progress | (8,436,196) | — | — | — | — | — | — | — |
| Net cash provided by (used in) investing activities | 97,479,281 | (116,183,868) | 5,108,210 | (35,072,507) | (1,196,286) | 5,439,206 | (3,002,050) | 4,671,937 |
| Cash flows from financing activities: | ||||||||
| Net proceeds from sale of common stock | 237,033,938 | 152,321,576 | 25,515,349 | 4,803,534 | 20,174,448 | 27,343,069 | 9,174,753 | 6,714,324 |
| Proceeds from loan payable | — | — | — | — | — | — | — | 0 |
| Proceeds from note payable | — | — | — | — | 0 | 318,160 | — | — |
| Proceeds from exercise of stock awards | — | — | — | — | 50,562 | 5,688,518 | 450 | — |
| Repurchase of fractional shares pursuant to reverse stock split | — | — | — | — | — | 0 | (193) | — |
| Proceeds from exercise of stock awards and warrants | — | 450,173 | — | — | — | — | — | — |
| Proceeds from exercise of stock awards and warrants | 11,858,358 | — | 64,601 | 70,304 | — | 32,403 | 2,772 | 139,140 |
| Net cash provided by financing activities | 248,892,296 | 152,771,749 | 25,579,950 | 4,873,838 | 20,225,010 | 33,382,150 | 9,177,782 | 6,853,464 |
| Net increase (decrease) in cash and cash equivalents | 276,560,316 | (3,407,861) | 5,091,615 | (25,282,032) | 2,219,400 | 28,766,546 | (645,769) | (2,337,040) |
| Cash and cash equivalents balance at beginning of period | 11,286,996 | 14,694,857 | 9,603,242 | 34,885,274 | 32,665,874 | 3,899,328 | 4,545,097 | 6,882,137 |
| Cash and cash equivalents balance at end of period | 287,847,312 | 11,286,996 | 14,694,857 | 9,603,242 | 34,885,274 | 32,665,874 | 3,899,328 | 4,545,097 |
| Supplemental disclosures of cash flow information: | ||||||||
| Interest paid in cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income taxes paid in cash | 1,600 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Initial recognition of right-of-use asset | 13,382,191 | — | — | — | — | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.